Likelihood of Approval and Phase Transition Success Rate Model – Nogapendekin Alfa in Colon Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Nogapendekin Alfa in Colon Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Nogapendekin Alfa in Colon Cancer Drug Details:
Nogapendekin alfa (Anktiva) is a interleukin-15 (IL-15) analogue. It is formulated as solution for intravesical route of administration. Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.Nogapendekin alfa (ALT-803) is under development for the treatment of various solid tumors like non-muscle invasive bladder cancer (NMIBC), non-small cell lung cancer, squamous non-small cell lung carcinoma, metastatic, ovarian cancer, hepatocellular carcinoma, metastatic colorectal cancer, gastric cancer, cervical cancer, renal cell carcinoma, metastatic melanoma, squamous cell head and neck carcinoma, urothelial carcinoma, Merkle cell carcinoma, small cell lung cancer, HIV infections, gastroesophageal (GE) junction carcinomas, adenocarcinoma of the gastroesophageal junction, hereditary nonpolyposis colon cancer (lynch syndrome), recurrent glioblastoma multiforme, gliosarcoma, metastatic castration resistant prostate cancer, triple-negative breast cancer (TNBC), endometrial cancer,and relapsed or refractory non-Hodgkin lymphoma. It is administered through intravesical, intravenous, intraperitoneal and subcutaneous route and acts by targeting IL2RG and IL2RB. The drug candidate was under development for the treatment of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primary peritoneal cancer, fallopian tube cancer, pancreatic cancer, refractory and relapsed multiple myeloma, refractory and relapsed acute myeloid leukemia, marginal zone b-cell lymphoma, Merkel cell carcinoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), B-cell non-Hodgkin lymphoma, chronic myelocytic leukemia (CML), follicular lymphoma and myelodysplastic syndrome.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Nogapendekin Alfa LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports